- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05526755
A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC) (TARGET)
An Open-label, Single-arm, Phase II, Multinational, Multicentre Study to Assess the Efficacy and Safety of 5 Years of Osimertinib in Participants With EGFRm-positive Stage II-IIIB NSCLC, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: AstraZeneca Clinical Study Information Center
- Phone Number: 1-877-240-9479
- Email: information.center@astrazeneca.com
Study Locations
-
-
-
Hong Kong, Hong Kong
- Recruiting
- Research Site
-
Hong Kong, Hong Kong, 150001
- Recruiting
- Research Site
-
-
-
-
-
Avellino, Italy, 83100
- Recruiting
- Research Site
-
Bergamo, Italy, 24127
- Recruiting
- Research Site
-
Brescia, Italy, 25123
- Recruiting
- Research Site
-
Lecce, Italy, 73100
- Recruiting
- Research Site
-
Lecco, Italy, 23900
- Recruiting
- Research Site
-
Milano, Italy, 20141
- Recruiting
- Research Site
-
Napoli, Italy, 80131
- Recruiting
- Research Site
-
Palermo, Italy, 90146
- Recruiting
- Research Site
-
Peschiera Del Garda, Italy, 37019
- Recruiting
- Research Site
-
Reggio Emilia, Italy, 42123
- Recruiting
- Research Site
-
Sondrio, Italy, 23100
- Recruiting
- Research Site
-
Terni, Italy, 05100
- Recruiting
- Research Site
-
Udine, Italy, 33100
- Recruiting
- Research Site
-
-
-
-
-
Busan, Korea, Republic of, 49241
- Recruiting
- Research Site
-
Busan, Korea, Republic of, 48108
- Recruiting
- Research Site
-
Cheongju-si, Korea, Republic of, 28644
- Recruiting
- Research Site
-
Daejeon, Korea, Republic of, 35015
- Recruiting
- Research Site
-
Goyang-si, Korea, Republic of, 410-769
- Recruiting
- Research Site
-
Gyeonggi-do, Korea, Republic of, 13620
- Recruiting
- Research Site
-
Incheon, Korea, Republic of, 21565
- Recruiting
- Research Site
-
Seongnam-si, Korea, Republic of, 13496
- Recruiting
- Research Site
-
Seoul, Korea, Republic of, 03722
- Recruiting
- Research Site
-
Seoul, Korea, Republic of, 05505
- Recruiting
- Research Site
-
Seoul, Korea, Republic of, 06591
- Recruiting
- Research Site
-
Seoul, Korea, Republic of, 06351
- Recruiting
- Research Site
-
Seoul, Korea, Republic of, 05030
- Recruiting
- Research Site
-
Seoul, Korea, Republic of, 03080
- Recruiting
- Research Site
-
Seoul, Korea, Republic of, 06273
- Recruiting
- Research Site
-
-
-
-
-
Kuala Lumpur, Malaysia, 59100
- Recruiting
- Research Site
-
Kuantan, Malaysia, 25100
- Recruiting
- Research Site
-
Kuching, Malaysia, 93586
- Recruiting
- Research Site
-
Petaling Jaya, Malaysia, 47500
- Recruiting
- Research Site
-
Sungai Petani, Malaysia, 08000
- Withdrawn
- Research Site
-
-
-
-
-
Bacolod, Philippines, 6100
- Recruiting
- Research Site
-
Cebu, Philippines, 6000
- Recruiting
- Research Site
-
Manila, Philippines, 1000
- Recruiting
- Research Site
-
Quezon City, Philippines, 1100
- Recruiting
- Research Site
-
-
-
-
-
Singapore, Singapore, 119074
- Recruiting
- Research Site
-
-
-
-
-
Badalona, Spain, 08013
- Recruiting
- Research Site
-
Barcelona, Spain, 08036
- Recruiting
- Research Site
-
Bilbao, Spain, 48013
- Recruiting
- Research Site
-
Granada, Spain, 18014
- Recruiting
- Research Site
-
L'Hospitalet de Llobregat, Spain, 08907
- Recruiting
- Research Site
-
Madrid, Spain, 28007
- Recruiting
- Research Site
-
Sevilla, Spain, 41009
- Recruiting
- Research Site
-
Valencia, Spain, 46026
- Recruiting
- Research Site
-
-
-
-
-
Hualien, Taiwan, 970
- Recruiting
- Research Site
-
Kaohsiung, Taiwan, 82445
- Recruiting
- Research Site
-
Kaohsiung City, Taiwan, 833401
- Recruiting
- Research Site
-
Taichung, Taiwan, 40705
- Recruiting
- Research Site
-
Taipei, Taiwan, 10449
- Recruiting
- Research Site
-
Taipei, Taiwan, 11259
- Recruiting
- Research Site
-
-
-
-
-
Bangkok, Thailand, 10700
- Recruiting
- Research Site
-
Phitsanulok, Thailand, 65000
- Withdrawn
- Research Site
-
Songkhla, Thailand, 90110
- Recruiting
- Research Site
-
-
-
-
-
Guildford, United Kingdom
- Withdrawn
- Research Site
-
London, United Kingdom, SW3 6JJ
- Recruiting
- Research Site
-
London, United Kingdom, W12 0HS
- Withdrawn
- Research Site
-
Nottingham, United Kingdom, NG5 1PB
- Recruiting
- Research Site
-
Surrey, United Kingdom, SM2 5PT
- Recruiting
- Research Site
-
-
-
-
Arizona
-
Yuma, Arizona, United States, 85364
- Recruiting
- Research Site
-
-
California
-
Los Angeles, California, United States, 90095
- Withdrawn
- Research Site
-
Santa Rosa, California, United States, 95403
- Recruiting
- Research Site
-
-
Maryland
-
Rockville, Maryland, United States, 20852
- Recruiting
- Research Site
-
-
Nevada
-
Las Vegas, Nevada, United States, 89169
- Recruiting
- Research Site
-
-
New York
-
White Plains, New York, United States, 10601
- Recruiting
- Research Site
-
-
Virginia
-
Fort Belvoir, Virginia, United States, 22060
- Withdrawn
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female aged at least 18 years.
- Histologically confirmed diagnosis of primary NSCLC on predominantly non-squamous histology.
- Magnetic Resonance Imaging (MRI) or contrast computed tomography (CT) scan of the brain.
- Participants must be classified post-operatively as Stage II, IIIA, or IIIB on the basis of surgical pathologic criteria.
- Confirmation by the local laboratory that the tumour harbours one of the two common EGFR mutations (Ex19del, L858R), either alone or in combination with other EGFR mutations including de novo EGFR mutation resulting in substitution of threonine with methionine at amino acid position 790 in exon 20 of EGFR (T790M) or uncommon EGFR mutations G719X, S768I, and L861Q, either alone, in combination with each other, or in combination with other uncommon EGFR mutations (excluding all exon 20 insertions) (Uncommon EGFRm Cohort).
- Complete surgical resection of the primary NSCLC is mandatory. All gross disease must have been removed at the end of surgery. All surgical margins of resection must be negative for tumour.
- Complete recovery from surgery and standard post-operative therapy (if applicable) at start of study intervention.
- World Health Organisation Performance Status of 0 to 1.
- Female participants must be using highly effective contraceptive measures, and must have a negative pregnancy test prior to start of dosing if of childbearing potential.
- Male participants must use effective barrier contraception.
Exclusion Criteria:
- Major surgery (including primary tumour surgery, excluding placement of vascular access) within 4 weeks prior to the first dose of study drug.
- Participants currently receiving medications or herbal supplements known to be potent inducers of CYP3A4 (at least 3 weeks prior to first dose).
- Participants who have had only segmentectomies or wedge resections.
- History of other malignancies, except: adequately treated non-melanoma skin cancer, curatively treated in situ cancer, or other solid tumours curatively treated with no evidence of disease for > 5 years following the end of study intervention.
Treatment with any of the following:
- Pre-operative or post-operative or planned radiation therapy for the current lung cancer.
- Pre-operative (neo-adjuvant) platinum-based or other chemotherapy.
- Any prior anticancer or immunological therapy, including investigational therapy, for treatment of NSCLC other than standard platinum-based doublet post-operative adjuvant chemotherapy.
- Prior treatment with neoadjuvant or adjuvant EGFR tyrosine kinase inhibitor (TKI).
- Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption of osimertinib.
Any of the following cardiac criteria:
- Mean resting corrected QT (QTc) interval > 470 msec, obtained from 3 electrocardiograms (ECGs).
- Any clinically important abnormalities in rhythm, conduction, or morphology of resting ECG.
- Any factors that increase the risk of QTc prolongation or risk of arrhythmic events.
- Heart failure, congenital long QT interval (QT) syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age in first-degree relatives or any concomitant medication known to prolong the QT interval and cause Torsades de Pointes (TdP).
- Past medical history of interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis that required steroid treatment, or any evidence of clinically active ILD.
- Inadequate bone marrow reserve or organ function.
- Women who are breastfeeding.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Osimertinib
Participants will receive osimertinib (AZD9291).
|
Participants will receive osimertinib (80 mg or 40 mg orally, once daily).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assess the Efficacy of Osimertinib as Measured by Disease Free Survival (DFS) [Common EGFRm Cohort].
Time Frame: From date of first dose until date of disease recurrence or death (by any cause in the absence of recurrence), up to approximately 5 years. Assessed at 5 years.
|
Defined as time from date of first dose until disease recurrence, or death due to any cause in the absence of recurrence.
|
From date of first dose until date of disease recurrence or death (by any cause in the absence of recurrence), up to approximately 5 years. Assessed at 5 years.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease Free Survival Rate at 3, 4 and 5 Years (Uncommon EGFRm Cohort)
Time Frame: From date of first dose until date of disease recurrence or death (by any cause in the absence of recurrence), up to approximately 5 years. Assessed at 3 years, 4 years, and 5 years.
|
Defined as the proportion of participants alive and disease free at 3, 4, and 5 years.
|
From date of first dose until date of disease recurrence or death (by any cause in the absence of recurrence), up to approximately 5 years. Assessed at 3 years, 4 years, and 5 years.
|
DFS Rate at 3 and 4 Years (Common EGFRm Cohort)
Time Frame: From date of first dose until date of disease recurrence or death (by any cause in the absence of recurrence), up to approximately 5 years. Assessed at 3 years, and 4 years.
|
Defined as the proportion of participants alive and disease free at 3, and 4 years.
|
From date of first dose until date of disease recurrence or death (by any cause in the absence of recurrence), up to approximately 5 years. Assessed at 3 years, and 4 years.
|
Overall Survival (OS) [Common EGFRm Cohort]
Time Frame: From date of first dose until the date of death due to any cause, up to approximately 5 years. Assessed at 3 years, 4 years, and 5 years.
|
Defined as time from date of first dose until the date of death due to any cause.
|
From date of first dose until the date of death due to any cause, up to approximately 5 years. Assessed at 3 years, 4 years, and 5 years.
|
Safety and tolerability in overall population (Common EGFRm Cohort and Uncommon EGFRm Cohort)
Time Frame: From date of first dose up to approximately 5 years
|
Adverse Events (AEs) graded by CTCAE version 5.0.
|
From date of first dose up to approximately 5 years
|
Recurrence events in overall population (Common EGFRm Cohort and Uncommon EGFRm Cohort)
Time Frame: From date of first dose up to approximately 5 years
|
Local/regional, or distant recurrence events assessed.
|
From date of first dose up to approximately 5 years
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Carcinoma
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Tyrosine Kinase Inhibitors
- Osimertinib
Other Study ID Numbers
- D5162C00048
- 2021-003024-33 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Qualified researchers can request access to anonymized individual participant-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment:
https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stage II-IIIB Non-small Cell Lung Carcinoma
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Merck Sharp & Dohme LLC; Rutgers Cancer Institute...Active, not recruitingStage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung CancerUnited States
-
Karen KellyBristol-Myers Squibb; National Cancer Institute (NCI); TransgeneCompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung CancerUnited States
-
Radiation Therapy Oncology GroupNational Cancer Institute (NCI); NRG OncologyActive, not recruitingStage II Non-Small Cell Lung Cancer AJCC v7 | Stage IIA Non-Small Cell Lung Carcinoma AJCC v7 | Stage IIB Non-Small Cell Lung Carcinoma AJCC v7 | Stage IIIA Non-Small Cell Lung Cancer AJCC v7 | Stage III Non-Small Cell Lung Cancer AJCC v7 | Stage IIIB Non-Small Cell Lung Cancer AJCC v7United States
-
H. Lee Moffitt Cancer Center and Research InstituteNestle Health ScienceWithdrawnNSCLC | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | NSCLC Stage IIIB | Non-small Cell Lung Cancer Stage IIIB | NSCLC, Stage IIIA | Non-small Cell Lung Cancer Stage ⅢAUnited States
-
AIO-Studien-gGmbHAstraZenecaTerminatedNSCLC | Non-squamous Non-small Cell Lung Cancer Stage II | Non-squamous Non-small Cell Lung Cancer Stage IIIA | Non-squamous Non-small Cell Lung Cancer Stage IIIB | Activating EGFR MutationGermany
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingRecurrent Lung Non-Small Cell Carcinoma | Stage II Non-Small Cell Lung Cancer AJCC v7 | Stage IIA Non-Small Cell Lung Carcinoma AJCC v7 | Stage IIB Non-Small Cell Lung Carcinoma AJCC v7 | Stage IIIA Non-Small Cell Lung Cancer AJCC v7 | Stage IIIB Lung Non-Small Cell Cancer AJCC v7United States
-
Emory UniversityNational Cancer Institute (NCI); National Institutes of Health (NIH); RefleXion...CompletedStage IB Non-Small Cell Lung Carcinoma AJCC v7 | Stage II Non-Small Cell Lung Cancer AJCC v7 | Stage IIA Non-Small Cell Lung Carcinoma AJCC v7 | Stage IIB Non-Small Cell Lung Carcinoma AJCC v7 | Stage I Lung Cancer | Stage II Lung Cancer | Stage I Non-Small Cell Lung Cancer AJCC v7 | Stage IA Non-Small...United States
-
National Cancer Institute (NCI)RecruitingStage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage II Lung Non-Small Cell Cancer AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7United States, Guam, Puerto Rico
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Bristol-Myers SquibbCompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage I Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung Carcinoma | Non-Squamous Non-Small...United States
-
Shanghai Pulmonary Hospital, Shanghai, ChinaNot yet recruitingStage II-IIIB(N2) Non-small Cell Lung CancerChina
Clinical Trials on Osimertinib 80 mg/40 mg
-
AstraZenecaActive, not recruitingStage IB-IIIA Non-small Cell Lung CarcinomaUnited States, Italy, Netherlands, Belgium, Canada, Poland, Romania, Taiwan, Thailand, Vietnam, France, Brazil, Hungary, Japan, Russian Federation, Turkey, China, Korea, Republic of, Germany, Hong Kong, Spain, Australia, Israel, Ukraine, Swed...
-
Genencell Co. Ltd.Recruiting
-
Caliway Biopharmaceuticals Co., Ltd.Completed
-
Medicines for Malaria VentureQ-Pharm Pty Limited; Clinical Network Services (CNS) Pty Ltd; QIMR Berghofer...Completed
-
JW PharmaceuticalRecruitingGoutKorea, Republic of
-
AstraZenecaParexelActive, not recruitingLocally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung CancerBelgium, United States, Canada, Poland, Romania, Taiwan, Thailand, Vietnam, France, Italy, Korea, Republic of, Brazil, Japan, Turkey, China, Malaysia, Germany, Spain, Australia, Hungary, Portugal, Switzerland, Israel, Philippines, Russian... and more
-
AstraZenecaCompletedCarcinoma, Non-Small-Cell Lung With EGFR Mutation PositiveChina
-
CARE Pharma Shanghai Ltd.Recruiting
-
Janssen Research & Development, LLCCompleted
-
UroGen Pharma Ltd.CompletedNeoplasms | Urologic Neoplasms | Urologic Diseases | Urinary Bladder Diseases | Urinary Bladder NeoplasmsIndia